This article is more than 5 years old. Information may no longer be current.

EVO+ Visian ICL receives CE mark

Issue: May 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The EVO+ Visian ICL with aspheric optic has received a CE mark for commercialization in the European Union, according to a STAAR Surgical press release.

Indicated for the correction or reduction of hyperopia and myopia between +3 D and –18 D, the EVO+ Visian ICL with aspheric (EDOF) optic is surgically implanted between the iris and the natural lens.

The company plans to introduce the lens to a group of surgeons for early effectiveness observational use, eliciting feedback from surgeons on the performance of the lens, patient acceptance and practice development, Caren Mason, STAAR Surgical president and CEO, said in the release.

“This represents an important new treatment option for eligible patients between 21 and 45 years of age living with nearsightedness or farsightedness,” she added.